Proton Pump Inhibitors and Electrolyte Disturbances

Introduction to PPI-Associated Risks

Proton pump inhibitors (PPIs) can cause hypomagnesemia, leading to hypokalemia, and are associated with an increased risk of anemia, particularly with long-term use, as noted by the American College of Gastroenterology 1

PPIs reduce gastric acid production, impairing iron absorption (particularly non-heme iron) and vitamin B12 absorption, according to the American Gastroenterological Association 1
Higher doses (≥1.5 PPI pills/day) are associated with a greater risk of iron deficiency (adjusted OR: 2.49; 95% CI: 2.35-2.64), as reported by the National Institute of Diabetes and Digestive and Kidney Diseases 1

Patients who require closer monitoring while on PPIs include those with Barrett's esophagus, eosinophilic esophagitis, high risk for upper GI bleeding, hypersecretory states like Zollinger-Ellison syndrome, as recommended by the American College of Gastroenterology and the American Gastroenterological Association 2, 2

The American Heart Association recommends using PPIs at the lowest effective dose and shortest duration possible to minimize the risk of electrolyte disturbances and anemia 1
Regular monitoring of electrolytes (magnesium, potassium, calcium) and complete blood count is essential for patients on long-term PPI therapy, as advised by the National Institute of Diabetes and Digestive and Kidney Diseases 1
Consider prophylaxis with PPIs for patients with intragastric balloons to prevent upper GI bleeding and erosions, using the lowest effective dose, frequency, and duration, as recommended by the American Gastroenterological Association 3
H2-receptor antagonists can be considered as alternatives to PPIs when appropriate, but avoid cimetidine due to its inhibitory effects on CYP2C19 4
Patients at increased risk for PPI-induced electrolyte disturbances include elderly patients, those with renal impairment, patients on medications affecting potassium levels, and patients with baseline electrolyte abnormalities, as well as cirrhotic patients who are at risk for hyponatremia and hepatic encephalopathy 4, 5
The American Gastroenterological Association emphasizes the importance of using the lowest effective dose and shortest duration of PPI therapy in certain patient populations 3